Prestige Links Sales Growth To Retailer, Consumer Supply-Chain Fears
Executive Summary
Retailer and consumer stockpiling in fear of supply chain disruptions drive double digit consumption growth for Prestige Consumer Healthcare’s Dramamine, Nix, Hydralyte and cough/cold brands. Brands drove total sales up 10.5% excluding impact of Akorn, to $12.4m in latest quarter.
You may also be interested in...
US Q4 Consumer Health Earnings Preview: Inflation Impact Follows Pandemic-Driven Disruption
Cost increases initially spurred by supply chain disruptions by COVID-19 pandemic have been noted by businesses across consumer product industries since soon after novel coronavirus spread accelerated in early 2020. More recently, OTC drug, nutritional supplement and personal care product providers began noting inflation’s influence on costs.
Prestige Consumer Feels ‘5-Ounce Hammer' From Pandemic Headwinds
Prestige hasn’t totally escaped supply chain disruptions caused by shutdowns during the pandemic but it’s relieved to report a smaller impact than most consumer-packaged goods marketers. Slower cough/cold OTC sales also don’t slow its results.
With TheraTears, Prestige Consumer Sees Way To Boost Guidance Despite COVID, Cost Uncertainties
More than 17% growth in consumer health product sales in latest quarter on top of adding TheraTears brands to its lineup at start of current quarter outweighs potential headwinds from costs and changes in consumer spending, Prestige Consumer executives say.